Lates News
In early trading on Thursday, shares of biopharmaceutical company Invivyd plummeted by 18%, after the company announced plans to raise $50 million through a securities offering. The funding will be used to support clinical projects, including research on monoclonal antibody therapy for long-term treatment of COVID-19.
Latest